Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies

M Page, E. I. Ekinci, R. M. Jones, P. W. Angus, P. J. Gow, R. C. O'Brien

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options. 

    Original languageEnglish
    Pages (from-to)601-604
    Number of pages4
    JournalInternal Medicine Journal
    Volume44
    Issue number6
    DOIs
    Publication statusPublished - Jun 2014

    Fingerprint

    Dive into the research topics of 'Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies'. Together they form a unique fingerprint.

    Cite this